|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: SPIN2B |
Gene summary for SPIN2B |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | SPIN2B | Gene ID | 474343 |
| Gene name | spindlin family member 2B | |
| Gene Alias | SPIN-2 | |
| Cytomap | Xp11.21 | |
| Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | A0A024R9Y9 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 474343 | SPIN2B | LZE7T | Human | Esophagus | ESCC | 2.33e-07 | 4.18e-01 | 0.0667 |
| 474343 | SPIN2B | LZE8T | Human | Esophagus | ESCC | 2.12e-02 | 1.17e-01 | 0.067 |
| 474343 | SPIN2B | LZE20T | Human | Esophagus | ESCC | 2.49e-04 | 1.14e-01 | 0.0662 |
| 474343 | SPIN2B | LZE24T | Human | Esophagus | ESCC | 8.23e-11 | 2.05e-01 | 0.0596 |
| 474343 | SPIN2B | P2T-E | Human | Esophagus | ESCC | 3.50e-07 | 1.01e-01 | 0.1177 |
| 474343 | SPIN2B | P4T-E | Human | Esophagus | ESCC | 2.97e-11 | 1.56e-01 | 0.1323 |
| 474343 | SPIN2B | P8T-E | Human | Esophagus | ESCC | 4.11e-07 | 9.65e-02 | 0.0889 |
| 474343 | SPIN2B | P9T-E | Human | Esophagus | ESCC | 5.25e-22 | 5.40e-01 | 0.1131 |
| 474343 | SPIN2B | P10T-E | Human | Esophagus | ESCC | 2.50e-10 | 1.80e-01 | 0.116 |
| 474343 | SPIN2B | P11T-E | Human | Esophagus | ESCC | 3.87e-04 | 2.24e-01 | 0.1426 |
| 474343 | SPIN2B | P12T-E | Human | Esophagus | ESCC | 2.27e-15 | 2.38e-01 | 0.1122 |
| 474343 | SPIN2B | P15T-E | Human | Esophagus | ESCC | 6.20e-03 | 9.53e-02 | 0.1149 |
| 474343 | SPIN2B | P16T-E | Human | Esophagus | ESCC | 2.50e-10 | 1.63e-01 | 0.1153 |
| 474343 | SPIN2B | P21T-E | Human | Esophagus | ESCC | 1.54e-05 | 1.19e-01 | 0.1617 |
| 474343 | SPIN2B | P22T-E | Human | Esophagus | ESCC | 3.04e-08 | 1.00e-01 | 0.1236 |
| 474343 | SPIN2B | P23T-E | Human | Esophagus | ESCC | 2.06e-10 | 2.22e-01 | 0.108 |
| 474343 | SPIN2B | P24T-E | Human | Esophagus | ESCC | 7.75e-04 | 1.09e-01 | 0.1287 |
| 474343 | SPIN2B | P26T-E | Human | Esophagus | ESCC | 5.86e-10 | 2.23e-01 | 0.1276 |
| 474343 | SPIN2B | P27T-E | Human | Esophagus | ESCC | 2.06e-03 | 6.97e-02 | 0.1055 |
| 474343 | SPIN2B | P28T-E | Human | Esophagus | ESCC | 8.35e-07 | 1.32e-01 | 0.1149 |
| Page: 1 2 3 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| SPIN2B | SNV | Missense_Mutation | c.691N>G | p.Gln231Glu | p.Q231E | Q9BPZ2 | protein_coding | deleterious(0.02) | possibly_damaging(0.693) | TCGA-BH-A0DX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | CR | |
| SPIN2B | SNV | Missense_Mutation | novel | c.233N>C | p.Ile78Thr | p.I78T | Q9BPZ2 | protein_coding | tolerated(0.67) | benign(0.043) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| SPIN2B | SNV | Missense_Mutation | c.428N>T | p.Ser143Phe | p.S143F | Q9BPZ2 | protein_coding | deleterious(0.02) | benign(0.231) | TCGA-EA-A78R-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| SPIN2B | SNV | Missense_Mutation | c.768A>T | p.Lys256Asn | p.K256N | Q9BPZ2 | protein_coding | deleterious(0) | possibly_damaging(0.771) | TCGA-ZJ-AAXB-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| SPIN2B | SNV | Missense_Mutation | novel | c.289N>A | p.Glu97Lys | p.E97K | Q9BPZ2 | protein_coding | deleterious(0.02) | possibly_damaging(0.812) | TCGA-A6-5657-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Ancillary | leucovorin | SD |
| SPIN2B | SNV | Missense_Mutation | novel | c.697N>A | p.Glu233Lys | p.E233K | Q9BPZ2 | protein_coding | tolerated(0.3) | benign(0.003) | TCGA-AA-3984-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| SPIN2B | SNV | Missense_Mutation | c.214N>A | p.Val72Ile | p.V72I | Q9BPZ2 | protein_coding | tolerated(0.22) | benign(0.003) | TCGA-AP-A056-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| SPIN2B | SNV | Missense_Mutation | c.749N>G | p.Tyr250Cys | p.Y250C | Q9BPZ2 | protein_coding | deleterious(0.01) | probably_damaging(0.998) | TCGA-AP-A05H-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Chemotherapy | carboplatin | SD | |
| SPIN2B | SNV | Missense_Mutation | novel | c.757N>A | p.Asp253Asn | p.D253N | Q9BPZ2 | protein_coding | tolerated(0.36) | probably_damaging(0.974) | TCGA-AP-A1DV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| SPIN2B | SNV | Missense_Mutation | rs772942286 | c.560N>A | p.Arg187His | p.R187H | Q9BPZ2 | protein_coding | tolerated(0.41) | benign(0) | TCGA-AX-A0J1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |